Latest It Distribution News

Regal Asian Investments has raised its semi-annual dividend target from 5 to 6 cents per share, supported by a robust profits reserve, signaling confidence in sustained shareholder returns.

Downer EDI Limited has announced a six-month ordinary dividend of AUD 0.108 per share, payable on March 27, 2025, with 75% franking. The dividend offers currency flexibility for New Zealand investors.

Regal Asian Investments Limited has announced a fully franked ordinary dividend of AUD 0.06 per share for the half-year ending December 2024, with a Dividend Reinvestment Plan available to shareholders.

Orora Limited reported a robust first half of FY25 with underlying EBIT rising 24.6%, driven by strategic portfolio simplification and organic growth investments despite challenges in the Australian wine market.

South32 Limited has announced a fully franked dividend of USD 0.034 per share for the six months ending December 2024, signaling steady shareholder returns amid a complex currency environment.

Northern Star Resources delivered strong half-year financials for FY25, showcasing significant growth in EBITDA and cash earnings while advancing its strategic acquisition of De Grey Mining.

Northern Star Resources has reported a robust half-year performance with record cash earnings and a significant interim dividend increase, reinforcing its commitment to shareholder value amid ongoing growth projects.

Northern Star Resources has announced a fully unfranked dividend of AUD 0.25 per share, payable on March 27, 2025, reflecting its financial results for the half-year ended December 31, 2024.

Orora Limited has announced a 5-cent per share ordinary dividend for the six months ending December 2024, payable in April 2025. The dividend is unfranked and offers shareholders a Dividend Reinvestment Plan option.

Origin Energy has announced a fully franked ordinary dividend of AUD 0.30 per share for the six months ending December 2024, signaling steady shareholder returns.

Treasury Wine Estates has announced a 20-cent per share dividend for the half-year ending December 2024, accompanied by a fully franked component and an active Dividend Reinvestment Plan.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.